3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
35
Breast Neoplasms
27
Prostatic Neoplasms
22
Stomach Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Neoplasms
10
Lung Neoplasms
10
Urinary Bladder Neoplasms
8
Head and Neck Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Squamous Cell
6
Non-Muscle Invasive Bladder Neoplasms
5
Nasopharyngeal Carcinoma
5
Carcinoma, Transitional Cell
5
Adenocarcinoma
5
Oropharyngeal Neoplasms
4
Sarcoma
3
Prostatic Neoplasms, Castration-Resistant
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
HER2-positive Breast Cancer
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Vaccinia
2
Recurrence
2
Peritoneal Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Interventions
pertuzumab
1
azeliragon
1
Trastuzumab
1
Docetaxel
1
Cyclophosphamide
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Cancer Related Cognitive Decline
×
Docetaxel
×
Clear all
NCT05256745
2025-12-24
RAGE
Georgetown University
Phase 1/2
Recruiting
48 enrolled